AIM: Functional @entity2210 , though benign, leads to deterioration of the quality of life and high costs for healthcare systems. The optimal therapy for functional @entity2210 is still to be defined because of its multifactorial pathogenesis. In an open multicentric study of @entity1 with functional @entity2210 , we prospectively evaluated the benefit of treatment with a food supplement composed of @entity14917 , @entity4959 , pineapple, @entity2732 , ginger, a-galactosidase and fennel (Perdiges, Bioten Snc, Turin, Italy). METHODS: Ninety-one consecutive @entity1 were included, suffering from functional @entity2210 , who had been previously submitted to therapy to eradicate the infection from @entity1534 ( @entity1534 ) and were waiting to perform the Urea Breath Test (UBT). The primary goal was to establish the percentage of @entity1 who continued to abstain from proton pump inhibitors (PPI) as they waited to carry out the UBT, differentiating between @entity1 who were treated (N.=55) with Perdiges and those who were not (N.=36). Our secondary goal was to document the differences within the 2 groups in terms of symptoms perceived between the start and end of the observation period. The wellness reported, during or in absence of treatment with Perdiges, was evaluated by the use of the VAS scale (Visual Analogical Scale) completed before the start of the treatment and after 30 days. RESULTS: All the @entity1 treated with Perdiges (55/55, 100%) and 31/36 (86.1%) @entity1 who were not (P=0.008) continued to abstain from PPI in the period awaiting the UBT. The VAS scale of those who took Perdiges improved on average by 1.78 points versus a worsening of 0.08 points of those who did not take it (P<0.0001). Furthermore, while among those who took Perdiges there was a statistically significant improvement (P<0.0001) in the VAS scale, between the baseline and the end of treatment, a worsening of 0.08 points (P=0.78) was noticed among the @entity1 who did not take it. CONCLUSION: Perdiges is significantly effective in the period following treatment to eradicate the infection from @entity1534 in @entity1 with functional @entity2210 . This allows to reduce the need to use antisecretive drugs. Further randomised studies, with wide ranging case histories, must assess its long-term efficacy.

Benefit of supplements in functional @entity2210 after treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity14917 :: ('MESH:C008970', 'Chemical') :: ['sodium alginate'] @entity4959 :: ('MESH:D002119', 'Chemical') :: ['carbonate calcium'] @entity2210 :: ('MESH:D004415', 'Disease') :: ['dyspepsia'] @entity2732 :: ('3649', 'Species') :: ['papaya'] @entity1534 :: ('210', 'Species') :: ['H. pylori', 'Helicobacter pylori']
@entity1534 :: (210,Species) :: ['Helicobacter pylori']
